COST-BENEFIT-ANALYSIS FOR THE USE OF HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE IN SANTIAGO, CHILE

Simple item page
dc.contributor.authorLEVINE, OS
dc.contributor.authorORTIZ, E
dc.contributor.authorCONTRERAS, R
dc.contributor.authorLAGOS, R
dc.contributor.authorVIAL, P
dc.contributor.authorMISRAJI, A
dc.contributor.authorFERRECCIO, C
dc.contributor.authorESPINOZA, C
dc.contributor.authorADLERSTEIN, L
dc.contributor.authorHERRERA, P
dc.contributor.authorCASAR, C
dc.date.accessioned2025-01-23T19:21:46Z
dc.date.available2025-01-23T19:21:46Z
dc.date.issued1993
dc.description.abstractCost-benefit analyses can be integral to the evaluation of interventions in developing countries. The authors compare the potential benefits to the Chilean Ministry of Health, in terms of treatment costs averted, by prevention of Haemophilus influenzae type b (HIB) invasive disease, with the costs of adding HIB conjugate vaccine to the diphtheria-tetanus-pertussis (DTP) immunization routinely administered to infants. In their base-case model, over a 10-year period (1991-2000), vaccination against HIB will prevent 1,229 cases of HIB invasive disease, including 713 cases of meningitis, 107 of whom would suffer severe, long-term sequelae, and between 29 and 116 deaths. Assuming a cost of US$1 for a full three-dose regimen of vaccine, the benefit/cost ratio of 1.66, with a net discounted savings of over $403,225, illustrates that HIB vaccine can be cost-beneficial. Sensitivity analyses which alter each of the variables in the analysis indicate that if the true incidence of HIB disease is twice the published rate, then three doses of vaccine remains cost-beneficial at US$3.
dc.fuente.origenWOS
dc.identifier.issn0002-9262
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/98863
dc.identifier.wosidWOS:A1993LM33700006
dc.issue.numero11
dc.language.isoen
dc.pagina.final1228
dc.pagina.inicio1221
dc.revistaAmerican journal of epidemiology
dc.rightsacceso restringido
dc.subjectCOST BENEFIT ANALYSIS
dc.subjectDEVELOPING COUNTRIES
dc.subjectHAEMOPHILUS-INFLUENZAE
dc.subjectIMMUNIZATION
dc.subjectMENINGITIS
dc.subjectPRIMARY PREVENTION
dc.subjectVACCINES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleCOST-BENEFIT-ANALYSIS FOR THE USE OF HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE IN SANTIAGO, CHILE
dc.typeartículo
dc.volumen137
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas